The Digester
health

FDA approves Foundayo oral GLP-1 for weight loss and Eli Lilly shares rise

The FDA approved Foundayo (orforglipron), an oral once daily GLP-1 that delivered about 12% mean weight loss in trials; prescriptions are being filled through LillyDirect with shipping from April 6 and wider retail availability to follow.

Apr 1st 2026 · United States

Insights

  • The FDA approved Foundayo (orforglipron), an oral once daily GLP-1 for weight loss.
  • Prescriptions are accepted immediately via LillyDirect with shipping beginning April 6 and the drug will later be available at retail pharmacies and telemedicine providers in the US.
  • In trials the highest dose produced a mean 12.4% weight loss (27.3 pounds) versus 0.9% (2.2 pounds) with placebo among completers, and participants overall lost 11.1% (25 pounds) versus 2.1% (5.3 pounds) with placebo.
  • Foundayo also reduced waist circumference, non HDL cholesterol, triglycerides and systolic blood pressure across doses in the ATTAIN program.
  • Eli Lilly said eligible commercially insured patients can pay $25 per month with a savings card, cash price starts at $149 per month for the lowest dose, Medicare Part D eligible patients may pay $50 per month from July 1, 2026, and the stock rose about 4% on Wall Street.

Sources